Abeona Therapeutics Inc vs Walt Disney Co — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Walt Disney Co trades at $103.53 (market cap $178.16B). The key difference: Walt Disney Co is far larger — about 419.9× Abeona Therapeutics Inc's market cap, and Walt Disney Co pays a 1.45% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | DIS | |
|---|---|---|
Market Cap | $424.33M | $178.16B |
Sector | Health | Media |
52-Week High | $7.45 | $118.86 |
52-Week Low | $4.17 | $92.40 |
Enterprise Value | $279.23M | $219.02B |
Volume | — | 7,546,013 |
Dividend Yield | — | 1.45% |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
Disney (DIS) trades at $103.51, down 1.32% on the day, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with four consecutive quarterly earnings beats, revenue growth to $94.43B in 2025, and improving profit margins. Recent news highlights advertising opportunities from major events and ongoing FCC regulatory challenges.
Outlook remains positive with analyst consensus target of $126 representing 22% upside potential. Key opportunities include streaming growth and theme park investments, while risks involve regulatory disputes and box office performance variability. Wall Street maintains strong buy sentiment with 62.5% of analysts recommending purchase.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →